Valo SPAC Presentation Deck

...designed to enable a new model of drug discovery and development rather than applying Al to the constrained, legacy model REINFORCING LEGACY Biological Discovery DOC -0-0-0-0-0-0-0-0- Ph II Ph III L L ІНННННН 1-0-0-0-0-0-0-0-0- Target ID OK PhI Reg ГЕННАНЕНЕЛЕНЕНОН -0-0-0-0-0-0-0-0- ГЕНЕРНЕНІНІНІНЕН Target to DOO ЕННННННН Hit Preclinical 10-------------- Comm LIFE SCIENCES INNOVATION Hit to Lead Lead Opt AI-DRIVEN Legacy biopharma model struggles to effectively integrate and leverage the full power of data & Al¹ VALO TRANSFORMATION CLINICAL DEVELOPMENT Reg Comm Phase III BIOLOGICAL DISCOVERY RWE Diagnosis Opal PLATFORM Phase II Target Discovery Phase I Preclinical Target ID Lead Opt Target to Hit Hit to Valo [1] Konersmann, Todd, et al. "Innovating R&D with the Cloud: Business Transformation Could Require Cloud-Enabled Ecosystems, and Services." Deloitte Insights, Deloitte Center for Health Solutions, (Dec 2020) Al Artificial Intelligence; Target ID = Target Identification; RWE = Real World Evidence; Lead Opt = Lead Optimization; Reg = Regulatory; Comm = Commercial THERAPEUTIC DESIGN Valo's drug acceleration model is designed to create an integrated process centered on data & Al 2Q21 11

View entire presentation